Volume 90 Issue 32 | p. 21 | Concentrates
Issue Date: August 6, 2012

Mersana Raises Cash, Teams With Adimab

Department: Business
Keywords: ADC, antibody-drug conjugates, biotech

Mersana Therapeutics has raised $27 million in a round of financing led by New Enterprise Associates, a new investor in the biotech firm. Pfizer Venture Investments is also a new investor in the financing round, which will help Mersana develop antibody-drug conjugates (ADCs). Separately, Mersana has teamed with Adimab to offer integrated antibody discovery and ADC technology. Adimab will optimize antibodies for use with Mersana’s Fleximer polymer and linker technology.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment